DNA Methyltransferase Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S8812 CM272 CM-272 is a novel first-in-class dual reversible inhibitor of G9a (GLP) and DNMTs with IC50 of 8 nM, 382 nM, 85 nM, 1200 nM, 2 nM for G9a, DNMT1, DNMT3A, DNMT3B, GLP, respectively. This compound prolongs survival in in vivo models of haematological malignancies by at least in part inducing immunogenic cell death.
Hepatol Commun, 2024, 8(2)e0378
Nat Med, 2019, 25(7):1073-1081
E4795 Bobcat339 Bobcat339 is a cytosine-based small molecule inhibitor of TET enzyme with IC50 of 33 μM and 73 μM for TET1 and TET2, respectively, reducing DNA 5hmC levels in hippocampal neurons. It is useful in epigenetics research and a potential starting point for therapeutics targeting DNA methylation and gene transcription.
Biomater Res, 2025, 29:0229
E1556 GSK-3484862 GSK-3484862 is a non-covalent, potent and selective inhibitor of DNMT1 with an IC50 of 0.23 μM. It demonstrates efficacy in acute myeloid leukemia.
S3543 DC-05 DC-05 is a DNA methyltransferase 1 (DNMT1) inhibitor, with an IC50 and a Kd of 10.3 μM and 1.09 μM, respectively.
S2477 2'-Deoxy-5-Fluorocytidine 2'-Deoxy-5-fluorocytidine (5-fluoro-2(')-deoxycytidine, FCdR), a pyrimidine analog, is a DNA methyltransferase (DMNT) inhibitor currently in clinical trials for solid tumors.
S2250 EGCG ((-)-Epigallocatechin Gallate) EGCG ((-)-Epigallocatechin Gallate) is the main catechin extraction of green tea that inhibits telomerase and DNA methyltransferase. EGCG blocks the activation of EGF receptors and HER-2 receptors. ECGG inhibits fatty acid synthase and glutamate dehydrogenase activity.
Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694
Cell Rep, 2025, 44(6):115799
Front Pharmacol, 2024, 15:1403424
Verified customer review of EGCG ((-)-Epigallocatechin Gallate)
S4294 Procainamide HCl Procainamide HCl is a sodium channel blocker, and also a DNA methyltransferase inhibitor, used in the treatment of cardiac arrhythmias.
Analytical Chemistry, January 12, 2024, 1547-1555
J Immunother Cancer, 2024, 12(11)e009805
Journal for ImmunoTherapy of Cancer, 2024, e009805